BridgeBio, Helsinn Partner Again After Truseltiq Success
Executive Summary
Deal Snapshot: The two firms will seek to co-develop and co-commercialize targeted small molecule cancer therapies that they identify at the preclinical stage.
You may also be interested in...
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Helsinn And BridgeBio Ink Infigratinib Cancer Pact
Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.